Insitro
Machine-learning drug discovery and development — Daphne Koller’s full-stack TherML platform pairs high-throughput cellular biology with deep-learning target identification and ChemML compound design, with multi-year partnerships with Bristol Myers Squibb, Eli Lilly and Gilead and a wholly-owned neuroscience-and-metabolic pipeline approaching the clinic in 2026.
The Business
Insitro builds the full-stack TherML (Therapeutic Machine Learning) platform for drug discovery and development, integrating high-throughput cellular biology, multi-modal deep learning for target identification and the ChemML compound-design stack added through the January 2026 CombinAbleAI acquisition. The platform now spans small molecules, oligonucleotides, antibodies and complex biologics. The commercial model combines three streams: partnership programs with named pharma companies (Bristol Myers Squibb on ALS and FTD with a March 2026 expansion adding ALS-2 and ALS-3 targets, Eli Lilly on the siRNA platform, Gilead on NASH), a wholly-owned pipeline focused on neuroscience and metabolic disease with lead candidate CTRO-1013 advancing toward first-in-human trials in 2026, and ongoing platform expansion (the CombinAbleAI acquisition and TherML launch in January 2026). The company is privately held — founded 2018 by Daphne Koller (ex-Calico CCO, ex-Coursera co-founder, Stanford CS faculty) — and has raised approximately $643M of external capital across three priced rounds, most recently the March 2021 $400M Series C led by Canada Pension Plan Investment Board.
Customers and Distribution
Insitro does not file public financials; the primary published commercial signals are the named pharma-partnership cohort (Bristol Myers Squibb, Eli Lilly, Gilead) underwriting the platform spend through milestone economics, the wholly-owned CNS pipeline approaching the clinic with CTRO-1013 advancing toward first-in-human trials in 2026, and the platform extension to full-modality scope post the January 2026 CombinAbleAI acquisition. Distribution sits across two channels: the named pharma-partnership channel (Bristol Myers Squibb originally five-year November 2020 collaboration expanded March 2026 with ALS-2 and ALS-3 targets; Eli Lilly siRNA platform 2023; Gilead NASH 2019) and the wholly-owned pipeline progression channel. The May 2025 22% workforce reduction was framed as a runway-extension move to 2027 rather than a strategic re-direction; the company has continued to ship platform-expansion announcements through 2026 including the CombinAbleAI acquisition and the TherML launch.
Model Strategy
Insitro is a Verticals-first play under the IM Framework eight-trajectories taxonomy as it applies to drug discovery: the strategic bet is that vertical depth on the ML-and-biology primitive — high-throughput cellular biology, multi-modal deep learning for target identification, ChemML compound design, and the full-modality TherML platform spanning small molecules, oligonucleotides, antibodies and biologics — beats horizontal generalist ML plays at the in-house drug-discovery and clinical-development task. The thesis explicitly bets on the integration of computational and wet-lab biology being the differentiating moat: TherML is not a software-only platform but a full-stack workflow that includes Insitro’s own biology generators (induced pluripotent stem cells, cellular imaging, multi-omics). The secondary trajectory is Pharma-Partnership Annuity: the Bristol Myers Squibb, Eli Lilly and Gilead collaborations underwrite the platform spend with milestone economics while the wholly-owned pipeline matures toward valuation-creating clinical readouts. The platform-modality-depth profile is the defining structural variable — the CombinAbleAI acquisition broadened the surface against modality-specialist competitors (Generate Biomedicines, EvolutionaryScale on proteins; AbCellera on antibodies) and the strategic question is whether full-stack depth across modalities outperforms modality-specialist depth in the long run.
At A Glance
The Numbers
Active pharma partnerships
Headcount (FTE)
Funding to date
Leadership Team
Insitro is privately held and the C-suite includes Founder/CEO Daphne Koller, CFO/CBO Mary Rozenman, CXO Ajamete Kaykas, and CMO S. Michael Rothenberg. Daphne Koller remains the public-facing anchor across every major announcement, which is meaningful continuity for an eight-year-old biotech and a strength on the leadership profile. The May 2025 22% workforce reduction announced by Koller was framed as a runway-extension move to 2027 rather than a strategic re-direction; the company has continued to ship platform-expansion announcements through 2026 including the CombinAbleAI acquisition and the TherML launch.
IM Framework Scoring
IM’s structured assessment of Insitro’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Mar 2021 | Series C | $400M | ~$2.5B | Canada Pension Plan Investment Board (CPP Investments) |
| May 2020 | Series B | $143M | — | Andreessen Horowitz |
| 2018 | Series A | $100M | — | Arch Venture Partners (with Andreessen Horowitz, Google Ventures, Third Rock) |
Cumulative external capital approximately $643M across three priced rounds, most recently the March 2021 $400M Series C led by Canada Pension Plan Investment Board with SoftBank Investment Advisors and continued participation from Andreessen Horowitz, Google Ventures, ARCH Venture Partners, Bezos Expeditions, T. Rowe Price, BlackRock, Casdin Capital and Foresite Capital. Round-by-round figures from named-press cycle (Fierce Biotech, MobiHealthNews, Endpoints News) and Insitro’s own newsroom. The May 2025 22% workforce reduction was framed as extending runway into 2027 rather than as a fresh capital event; no new priced round has been disclosed since 2021.
Competitive Landscape
Insitro’s competitive set sits in three concentric rings: the public-listed ML-biology platform companies (Recursion, AbCellera), the Alphabet-backed and Flagship-backed deeper-capital platform plays (Isomorphic Labs, Generate Biomedicines), and the generative-protein-design cohort emerging in 2024-2025 (EvolutionaryScale, Chai Discovery, Latent Labs and others). Insitro is unusual in the set because the TherML platform now explicitly spans the full small-molecule / oligonucleotide / antibody / biologic stack post the January 2026 CombinAbleAI acquisition, whereas most competitors specialise in a narrower modality. The strategic-investor cohort (Andreessen Horowitz, Google Ventures, ARCH Venture Partners, CPP Investments, SoftBank Investment Advisors) and the named pharma partnerships with Bristol Myers Squibb, Eli Lilly and Gilead set the funded-platform-plus-partnership-annuity competitive frame.
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Recursion Pharmaceuticals ((NASDAQ: RXRX)) |
Public-listed ML-biology platform company with a large in-house cellular-imaging dataset and a deep ML compound-discovery stack; pipeline programs across oncology, rare disease and neuroscience. Closed the Exscientia acquisition in 2024 to add structure-based design to the platform. | Public-market access to capital plus pharma partnerships with Bayer and Roche; broad multi-modal disease focus across oncology, rare disease and CNS. | High — the most direct ML-biology competitive substitute with a public-market valuation re-mark and a comparable platform thesis; pipeline progression and partnership economics provide direct benchmarks for the Insitro platform’s commercial validation. |
| Isomorphic Labs (Alphabet) |
Drug discovery platform anchored by AlphaFold-3 protein-structure prediction and a deep-learning compound-design stack; founded by Demis Hassabis and operated under Alphabet ownership. Multi-billion-dollar partnership with Novartis and Eli Lilly announced 2024. | Alphabet capital backing plus the named Novartis and Eli Lilly partnership economics; deep DeepMind research lineage. | High — structurally well-funded competitor with the Alphabet capital base and the AlphaFold platform differentiation; competes for the same partnership-economics market with the major pharma buyers. |
| Generate Biomedicines ((Flagship Pioneering)) |
Generative biology platform from Flagship’s bioplatform franchise; deep generative-model focus on protein design across antibodies, peptides and other modalities. Multi-year Amgen partnership and a Series C round in late 2023. | Flagship Pioneering capital plus named partnerships with Amgen and other pharma buyers; deeper generative-protein focus than Insitro’s small-molecule emphasis. | Medium-high — competitive overlap on the protein-design surface; narrower than Insitro on the small-molecule / oligonucleotide stack the TherML platform now spans post-CombinAbleAI acquisition. |
| EvolutionaryScale | ESM3-anchored generative biology lab founded by ex-Meta FAIR protein team in 2024; deep generative-protein-design thesis with a closed-source ESM3 release positioned for biotech and pharma customers. | Direct platform-licensing motion to biotech and pharma; partnership cohort still being built out as the company is in its first 24 months. | Medium — flanking risk on the protein-design surface; less competitive on Insitro’s small-molecule / clinical-pipeline thesis but a direct platform-competition signal. |
| AbCellera Biologics ((NASDAQ: ABCL)) |
Antibody-discovery platform with public-listed status and a deep enterprise partnership cohort including Pfizer, Eli Lilly and AbbVie. Strong in antibody discovery specifically rather than across the modality stack Insitro now spans. | Public-market capital access plus the named pharma partnership cohort; modality-focused on antibodies rather than multi-modal. | Medium — competitive overlap on the antibody-platform layer post the CombinAbleAI acquisition adds antibody modality to TherML; narrower than Insitro on the small-molecule and oligonucleotide stack. |
Commercial frame: Insitro’s revenue today is dominated by milestone and research payments from the Bristol Myers Squibb (ALS / FTD), Eli Lilly (siRNA platform) and Gilead (NASH) collaborations, with the wholly-owned pipeline pre-clinical and the lead candidate CTRO-1013 advancing toward first-in-human trials in 2026. Pharma-partnership economics across the cohort typically run upfront + research funding + milestone payments + royalties, with Bristol Myers Squibb’s March 2026 expansion adding ALS-2 and ALS-3 targets to the original five-year November 2020 collaboration. Recursion, Isomorphic Labs, Generate Biomedicines and AbCellera operate on broadly comparable structures with varying upfront / milestone / royalty mixes; the public-listed comparables (Recursion, AbCellera) provide the cleanest valuation benchmarks for the ML-biology platform-plus-pipeline thesis.
Potential Risks
The case for Insitro at IM Framework 6.43 rests on Daphne Koller’s category-defining ML-and-biology thesis anchored by her Stanford CS / Coursera / Calico lineage, the full-stack TherML platform that now spans small molecules, oligonucleotides, antibodies and biologics post the January 2026 CombinAbleAI acquisition, the named pharma-partnership cohort with Bristol Myers Squibb (expanded March 2026 to include ALS-2 and ALS-3 targets), Eli Lilly (siRNA platform) and Gilead (NASH) underwriting the platform spend, the wholly-owned CNS pipeline approaching the clinic with CTRO-1013 advancing toward first-in-human trials in 2026, and a strategic-investor cohort (Andreessen Horowitz, Google Ventures, ARCH Venture Partners, Canada Pension Plan Investment Board, SoftBank Investment Advisors, Bezos Expeditions, T. Rowe Price, BlackRock, Casdin Capital, Foresite Capital) that has backed the trajectory across three rounds. The case against splits into five risks of differing magnitude — with time-to-revenue and clinical-validation execution the most structural, pharma-partnership dependency the most active commercial concentration variable, and competitive substitution from Recursion, Isomorphic Labs and the generative-protein cohort the most watched.
Time-to-revenue and clinical-validation execution
Insitro’s wholly-owned pipeline remains pre-clinical with CTRO-1013 advancing toward first-in-human trials in 2026; the validation event for the TherML platform is therefore years out and depends on multiple clinical milestones the company has not yet hit. The May 2025 22% workforce reduction was framed as a runway-extension move to 2027 rather than as a strategic re-direction, but it explicitly tied the company’s next funding cycle to the clinical milestones the wholly-owned pipeline must hit before the runway exhausts. Time-to-revenue execution is the principal structural risk on the disruption composite.
Pharma-partnership dependency and renegotiation cycle
The Bristol Myers Squibb (originally five-year November 2020 collaboration, expanded March 2026), Eli Lilly (siRNA platform 2023) and Gilead (NASH 2019) partnerships underwrite the platform spend through milestone economics, but each is structured around fixed-term collaboration cycles that come up for renegotiation. The Bristol Myers Squibb expansion is a positive signal for collaboration durability; the Gilead NASH program is now several years into its life. The dependency on three named pharma partners is the most-watched commercial concentration variable.
Competitive substitution — Recursion, Isomorphic, Generate, AbCellera and the generative-protein cohort
Recursion’s public-market access to capital plus the Exscientia acquisition, Isomorphic Labs’s Alphabet backing plus the Novartis and Eli Lilly partnerships, Generate Biomedicines’s Flagship capital plus the Amgen partnership, EvolutionaryScale’s ESM3 release and Chai Discovery’s generative-protein-design platform all compete in the same ML-biology lane for the same pharma-partnership economics. None has matched Insitro’s combination of full-modality TherML platform + three named pharma partners + advanced wholly-owned CNS pipeline, but every named competitor is escalating into the same lane and several have meaningfully larger capital bases.
Capital runway and absence of post-2021 funding cycle
The March 2021 $400M Series C remains the most recent priced round; the May 2025 workforce reduction extended the runway to 2027 rather than initiating a new funding cycle. If the wholly-owned pipeline clinical milestones do not advance on the disclosed schedule, the next funding cycle becomes a binding constraint. Cumulative external capital of approximately $643M is competitive against most ML-biology private peers but materially smaller than Isomorphic Labs’s Alphabet capital backing and below the public-market access of Recursion. The watched event is whether a new partnership signal or fresh capital cycle re-marks the platform value before runway pressure intensifies.
Platform-modality breadth vs depth trade-off
The January 2026 CombinAbleAI acquisition and TherML launch extended the platform to span small molecules, oligonucleotides, antibodies and complex biologics — a positive depth signal but one that broadens the competitive surface against modality-specialist competitors (Generate Biomedicines and EvolutionaryScale on proteins, AbCellera on antibodies, Recursion on cellular imaging). The strategic question is whether full-stack TherML depth across modalities outperforms modality-specialist depth in the long run; the answer requires clinical-validation events that are years out.
Recent IM Coverage
Show recent press coverage of Insitro
- Mar 2026 — Insitro and Bristol Myers Squibb collaboration expanded with nomination of new targets — ALS-2 and ALS-3 added under the existing five-year collaboration.
- Jan 2026 — Insitro to acquire CombinAbleAI to complete its full stack, modality-agnostic AI platform for drug discovery and design — launch of TherML platform.
- May 2025 — Insitro, an AI biotech founded by Daphne Koller, lays off staff — 22% workforce reduction extends runway into 2027.
- Mar 2021 — Insitro’s AI drug discovery platform pulls another $400M from investors led by Canada Pension Plan Investment Board.
- Mar 2021 — Insitro nets $400M Series C to ramp up machine learning drug discovery.
- Oct 2020 — Insitro announces five-year discovery collaboration with Bristol Myers Squibb to discover and develop novel treatments for ALS and FTD.
Curated feed of named-source coverage — Insitro’s own newsroom and the named-press cycle around the company’s funding, partnership and pipeline milestones. We exclude PR-wire reposts of the same release, aggregator round-up pieces and subscription-research summaries. The Insitro newsroom is the canonical primary anchor for the CombinAbleAI acquisition, the TherML launch, the Bristol Myers Squibb expansion and the broader pipeline progression cited on this page.
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Insitro is privately held and does not file public financials. Revenue today is dominated by milestone and research-funding payments from the Bristol Myers Squibb collaboration, the Eli Lilly siRNA platform partnership and the Gilead NASH collaboration; the wholly-owned pipeline is pre-clinical. We decline-to-publish a precise revenue figure pending a primary disclosure.
- Pipeline and partnerships: Insitro’s March 2026 collaboration expansion with Bristol Myers Squibb added ALS-2 and ALS-3 targets to the original five-year November 2020 collaboration; the January 2026 CombinAbleAI acquisition and TherML launch extended the platform to span small molecules, oligonucleotides, antibodies and biologics. The wholly-owned pipeline anchor candidate CTRO-1013 is advancing CMC and FIH trial design with first-in-human trials targeted in 2026 per the company’s own newsroom disclosure.
- Headcount: Following the May 2025 22% workforce reduction Daphne Koller disclosed via internal communications, the company employed approximately 230 staff post-reduction per STAT News reporting; BioSpace coverage of the same announcement cited the runway extension to 2027. We reference the STAT News and BioSpace coverage as the primary anchors and decline-to-publish a precise current headcount pending a fresh primary disclosure.
- Funding to date: Cumulative external capital approximately $643M across three priced rounds — May 2020 $143M Series B led by Andreessen Horowitz, March 2021 $400M Series C led by Canada Pension Plan Investment Board with SoftBank Investment Advisors and continued participation from Andreessen Horowitz, Google Ventures, ARCH Venture Partners, Bezos Expeditions, T. Rowe Price, BlackRock, Casdin Capital and Foresite Capital. Prior 2018 $100M Series A led by ARCH Venture Partners is the canonical founding-round figure.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
